Amanda Gollo Bertollo

Dr. Amanda Gollo Bertollo

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
GSGilnei Bruno da Silva
Gilnei Bruno da Silva
DMDaiane Manica
Daiane Manica
ASAlana Patrícia da Silva
Alana Patrícia da Silva
GKGreicy Cristine Kosvoski
Greicy Cristine Kosvoski
MHMarceli Cleunice Hanauer
Marceli Cleunice Hanauer
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI

9 September 2024 in Reviews in the Neurosciences
Verified
Journal Article
Closed access
Amanda Gollo BertolloAmanda Gollo Bertollo
Amanda Gollo Bertollo
MMMaiqueli Eduarda Dama Mingoti
Maiqueli Eduarda Dama Mingoti
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
Major depressive disorder (MDD) is a prevalent psychiatric disorder that has damage to people’s quality of life. Tryptophan is the precursor to serotonin, a critical neurotransmitter in mood modulation. In mammals, most free tryptophan is degraded by the kynurenine pathway (KP), resulting in a range of metabolites involved in inflammation, immune response, and neurotransmission. The imbalance between quinolinic acid (QA), a toxic metabolite, and kynurenic acid (KynA), a protective metabolite, is a relevant phenomenon involved in the pathophysiology of MDD. Proinflammatory cytokines increase the activity of the enzyme indoleamine 2,3-dioxygenase (IDO), leading to the degradation of tryptophan in the KP and an increase in the release of QA. IDO activates proinflammatory genes, potentiating neuroinflammation and deregulating other physiological mechanisms related to chronic stress and MDD. This review highlights the physiological mechanisms involved with stress and MDD, which are underlying an imbalance of the KP and discuss potential therapeutic targets.

14 March 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Amanda Gollo BertolloAmanda Gollo Bertollo
Amanda Gollo Bertollo
CPCamila Ferreira Puntel
Camila Ferreira Puntel
BSBrunna Varela da Silva
Brunna Varela da Silva
MMMartins Marcio
Martins Marcio
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), neurodevelopmental disorders (NDDs) are a group of conditions that arise early in development and are characterized by deficits in personal, social, academic, or occupational functioning. These disorders frequently co-occur and include conditions such as autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD). Mood disorders (MDs), such as major depressive disorder and bipolar disorder, also pose significant global health challenges due to their high prevalence and substantial impact on quality of life. Emerging evidence highlights overlapping neurobiological mechanisms between NDDs and MDs, including shared genetic susceptibilities, neurotransmitter dysregulation (e.g., dopaminergic and serotonergic pathways), neuroinflammation, and hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Environmental factors such as early-life adversity further exacerbate these vulnerabilities, contributing to the complexity of their clinical presentation and comorbidity. Functional neuroimaging studies reveal altered connectivity in brain regions critical for emotional regulation and executive function, such as the prefrontal cortex and amygdala, across these disorders. Despite these advances, integrative diagnostic frameworks and targeted therapeutic strategies remain underexplored, limiting effective intervention. This review synthesizes current knowledge on the shared neurobiological underpinnings of NDDs and MDs, emphasizing the need for multidisciplinary research, including genetic, pharmacological, and psychological approaches, for unified diagnosis and treatment. Addressing these intersections can improve clinical outcomes and enhance the quality of life for individuals affected by these disorders.

11 September 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Amanda Gollo BertolloAmanda Gollo Bertollo
Amanda Gollo Bertollo
RMRicieri Mocelin
Ricieri Mocelin
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
Purpose: Genetic polymorphisms within specific genes play a role in both the genetic predisposition to Major Depressive Disorder (MDD) and the variation observed in responses to antidepressant treatments. Pharmacogenetics examines how these polymorphisms affect medication response. This review highlights significant disparities in the pharmacogenetic influences on antidepressant response, with a focus on ethnic and sex-based differences. Methods: This review synthesizes findings from a comprehensive literature search conducted between 2000 and 2025. It utilized databases such as PubMed, Scopus, and Web of Science, using search terms including “pharmacogenetics”, “antidepressants”, “Major Depressive Disorder”, “CYP450”, “neuroplasticity”, and “genetic variations”. This review integrates pharmacogenetics with neurotransmitters and their transporters, neuroplasticity, growth factors, and the cytochrome P450 family, providing promising insights for personalized MDD treatment strategies. We analyzed and synthesized findings from over 50 relevant studies, focusing on those with a clear emphasis on genetic associations with antidepressant efficacy and adverse effects. Results: Pharmacogenetic analysis facilitates personalized antidepressant prescriptions by identifying key genetic variants that influence treatment outcomes. Specifically, variations in CYP2D6 and CYP2C19 can significantly impact drug metabolism and tolerability. A high percentage of patients with non-normal metabolizer phenotypes are predisposed to adverse drug reactions or ineffective responses. Furthermore, this review identifies significant ethnic and sex-based disparities in treatment response. For example, the L allele of the 5-HTTLPR polymorphism confers a higher likelihood of response and remission following SSRI treatment in white people compared to Asians. Additionally, in women, specific 5-HTTLPR polymorphisms have a more pronounced influence on mood and MDD pathophysiology, with a significant reduction in mood in response to tryptophan depletion. Conclusions: Integrating pharmacogenetic insights, encompassing genetic factors, neurotransmitter pathways, neuroplasticity, and the influence of ethnicity and sex, is crucial for developing personalized antidepressant treatment strategies. This will ultimately optimize patient recovery and minimize adverse effects.

5 October 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Amanda Gollo BertolloAmanda Gollo Bertollo
Amanda Gollo Bertollo
GBGeórgia de Carvalho Braga
Geórgia de Carvalho Braga
PTPaula Teresinha Tonin
Paula Teresinha Tonin
ALAdriana Remião Luzardo
Adriana Remião Luzardo
MBMARGARETE DULCE BAGATINI
MARGARETE DULCE BAGATINI
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
The COVID-19 pandemic generated, in addition to severe symptoms, hospitalizations and deaths worldwide, as well as stress from the fear of the disease and social uncertainties, from restriction measures and social isolation. Stress from social isolation impacts mental health, aggravating existing conditions and triggering neuropsychiatric symptoms in individuals with biopsychosocial vulnerability. During and immediately after the period of social restriction imposed by the pandemic, the scientific community carried out several research protocols. These revealed results that relevantly demonstrate the harmful effect of the stress induced by the pandemic situation. This narrative review reports and discusses research results demonstrating impairments in psychiatric disorders such as autism spectrum disorder, dementia, eating disorders, schizophrenia, anxiety, and depression. In this sense, the community has identified a significant negative influence of social isolation on the mental health of individuals through the modification of individual routines and the absence of social interactions. Moreover, the community identified perceived differences related to the impacts on men and women. In addition to studies showing the effect of social isolation on disorders, an evaluation of protocols with some possible therapeutic intervention strategies during times of social restriction was developed.

1 January 2024 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
Amanda Gollo BertolloAmanda Gollo Bertollo
Amanda Gollo Bertollo
AGAgatha Carina Leite Galvan
Agatha Carina Leite Galvan
MMMaiqueli Eduarda Dama Mingoti
Maiqueli Eduarda Dama Mingoti
CDClaudia Dallagnol
Claudia Dallagnol
ZIZuleide Maria Ignácio
Zuleide Maria Ignácio
Anxiety and depression are prevalent mental disorders around the world. The etiology of both diseases is multifactorial, involving biological and psychological issues. The COVID-19 pandemic settled in 2020 and culminated in several changes in the routine of individuals around the world, affecting mental health. People infected with COVID-19 are at greater risk of developing anxiety and depression, and individuals previously affected by these disorders have worsened the condition. In addition, individuals diagnosed with anxiety or depression before being affected by COVID-19 developed the severe illness at higher rates than individuals without mental disorders. This harmful cycle involves several mechanisms, including systemic hyper-inflammation and neuroinflammation. Furthermore, the context of the pandemic and some previous psychosocial factors can aggravate or trigger anxiety and depression. Disorders are also risks for a more severe picture of COVID-19. This review discusses research on a scientific basis, which brings evidence on biopsychosocial factors from COVID-19 and the context of the pandemic involved in anxiety and depression disorders.